<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Gene test interpretation: &lt;i&gt;CHEK2&lt;/i&gt;
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Gene test interpretation:
       <i>
        CHEK2
       </i>
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Gene test interpretation:
        <i>
         CHEK2
        </i>
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Authors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Beth N Peshkin, MS, CGC
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Claudine Isaacs, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Harold J Burstein, MD, PhD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Anne Slavotinek, MBBS, PhD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Shilpa Grover, MD, MPH, AGAF
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Sadhna R Vora, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Jul 07, 2022.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H138311032">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         This monograph summarizes the interpretation of germline testing of the
         <em>
          CHEK2
         </em>
         gene. It does
         <strong>
          not
         </strong>
         discuss indications for testing and is not intended to replace clinical judgment in the decision to test or in the clinical care of the individual who was tested. These subjects are discussed separately [
         <a href="#rid1">
          1
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1057519981">
         <span class="h1">
          OVERVIEW
         </span>
        </p>
        <p class="headingAnchor" id="H3917961410">
         <span class="h2">
          How to read the report
         </span>
         <span class="headingEndMark">
          —
         </span>
         An approach to reviewing a genetic test report is summarized in the checklist  (
         <a class="graphic graphic_table graphicRef122437" href="/z/d/graphic/122437.html" rel="external">
          table 1
         </a>
         ).
        </p>
        <p>
         Testing involves two steps by the laboratory: determining the genotype and interpreting the pathogenicity of the variant(s).
        </p>
        <p>
         The pathogenicity of each variant is classified by the laboratory into one of five categories  (
         <a class="graphic graphic_table graphicRef122646" href="/z/d/graphic/122646.html" rel="external">
          table 2
         </a>
         ), using information available at the time [
         <a href="#rid2">
          2
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2682924572">
         <span class="h2">
          Classification of variants
         </span>
         <span class="headingEndMark">
          —
         </span>
         The classification for many variants such as those deemed "likely pathogenic" or "variants of uncertain significance" (VUS) is periodically updated as more data become available [
         <a href="#rid3">
          3
         </a>
         ]. The uncertainty reflects the available research rather than the accuracy of genotyping.
        </p>
        <p>
         If there is concern about the classification, such as for a VUS or low-penetrance variant, obtain an updated interpretation periodically (eg, annually), when clinical management or reproductive decisions might be altered or if family members present for genetic testing. This can be done by checking a database such as
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fclinvar%2F&amp;token=wEsKVFvqlKzpT%2BqOtddW%2Fy3%2BLj0shalBW%2BL1ZyL4trzGy12ipcVcj41059JRLkL3&amp;TOPIC_ID=135009" target="_blank">
          ClinVar
         </a>
         , contacting the laboratory, or consulting a specialist, clinical geneticist or genetic counselor; there is no gold standard approach. Some laboratories routinely provide updates and others provide more information only when requested. Many VUS are reclassified as benign. Likely benign and benign variants are not routinely reported.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Genotype
         </strong>
         – Identifies the variants in the gene(s) tested. If the results were obtained by direct-to-consumer testing or a research study, testing should be repeated, possibly in conjunction with additional gene tests, in a Clinical Laboratory Improvement Amendments (CLIA)-certified laboratory (or other nationally certified laboratory). This is particularly true if test results would impact clinical care of the patient and/or their relatives (eg, pathogenic variant identified in a gene with known clinical significance/potential clinical actionability; negative finding in an individual with a suspected cancer syndrome or whose family member is known to carry a pathogenic variant).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Interpretation
         </strong>
         – Determines pathogenicity of the variant(s) identified and presents a classification of such based on standard criteria. May require updating, particularly for VUS, as new research and data are available. (See
         <a class="local">
          'Variant of uncertain significance'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p>
         Note that it is critical to review the test report carefully. Risk information and associated management recommendations for variants in the
         <em>
          CHEK2
         </em>
         gene are dependent on the specific variant identified.
        </p>
        <p>
         The table provides a glossary of genetic testing terms  (
         <a class="graphic graphic_table graphicRef122429" href="/z/d/graphic/122429.html" rel="external">
          table 3
         </a>
         ).
        </p>
        <p class="headingAnchor" id="H867489852">
         <span class="h1">
          PATHOGENIC OR LIKELY PATHOGENIC VARIANT
         </span>
        </p>
        <p class="headingAnchor" id="H2211532525">
         <span class="h2">
          Disease associations
         </span>
         <span class="headingEndMark">
          —
         </span>
         The checkpoint kinase 2 (
         <em>
          CHEK2
         </em>
         ) gene is associated with the DNA damage repair response Fanconi anemia (FA)-
         <em>
          BRCA1/2
         </em>
         pathway. Several
         <em>
          CHEK2
         </em>
         pathogenic variants have been identified, but risks may be different based on the specific variant identified.
        </p>
        <p>
         <em>
          CHEK2
         </em>
         is considered a moderate risk cancer gene. Transmission of the cancer risk associated with
         <em>
          CHEK2
         </em>
         variants is autosomal dominant with incomplete penetrance. Heterozygosity for a pathogenic or likely pathogenic variant in
         <em>
          CHEK2
         </em>
         is associated with increased lifetime risks for several cancers, but many individuals will not develop cancer. The most commonly studied variants are c.1100delC and c.Ile157Thr (c.I157T).
        </p>
        <p>
         Protein-truncating or frameshift variants in
         <em>
          CHEK2
         </em>
         are associated with an increased risk for breast cancer. The c.1100delC protein-truncating variant, predominantly seen in White Americans and Europeans of Northern or Eastern European descent, is associated with a two- to threefold increased risk of breast cancer [
         <a href="#rid4">
          4-17
         </a>
         ]. The cumulative breast cancer risk in females with this variant has been reported to be approximately six percent to age 49 and 32 percent to age 80 [
         <a href="#rid18">
          18
         </a>
         ]. In general, breast cancer lifetime risks for frameshift variants in
         <em>
          CHEK2
         </em>
         ranges from 15 to 40 percent and appear to be higher when an individual has a family history of breast cancer [
         <a href="#rid17">
          17,19,20
         </a>
         ].
        </p>
        <p>
         Cancer risks associated with most pathogenic missense variants in
         <em>
          CHEK2
         </em>
         are unclear, but are likely lower than protein-truncating variants. For example, the c.Ile157Thr variant has been associated with only a modest increase in breast cancer risk (odds ratio [OR] 1.58, 95% CI 1.42-1.75) [
         <a href="#rid21">
          21
         </a>
         ]. In a separate report, cumulative age-specific breast cancer risks for the c.Ile157Thr variant were approximately 3 percent to age 49 and 18 percent to age 80 [
         <a href="#rid18">
          18
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/785.html" rel="external">
          "Overview of hereditary breast and ovarian cancer syndromes", section on 'CHEK2'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1342977272">
         <span class="h2">
          Clinical features
         </span>
        </p>
        <p class="headingAnchor" id="H1654172300">
         <span class="h3">
          Cancer risks
         </span>
         <span class="headingEndMark">
          —
         </span>
         Discussion should include the range of cancer risks, possible interventions for surveillance or risk reduction, and implications for first-degree and more distant relatives (see
         <a class="local">
          'Genetic testing of at-risk relatives'
         </a>
         below). The discussion of risks is individualized based on the person's age, family history of cancer, and the specific
         <em>
          CHEK2
         </em>
         variant identified. It is therefore important to read the test report carefully for information about the variant identified and the current interpretation of that variant.
        </p>
        <p class="headingAnchor" id="H1974245920">
         <span class="h4">
          Breast cancer
         </span>
         <span class="headingEndMark">
          —
         </span>
         Pathogenic and likely pathogenic frameshift germline variants in
         <em>
          CHEK2
         </em>
         confer an increased risk of breast cancer, with lifetime risks ranging from 15 to 40 percent [
         <a href="#rid19">
          19
         </a>
         ]. Although specific data are lacking on other
         <em>
          CHEK2
         </em>
         pathogenic/likely pathogenic variants, we usually counsel individuals with protein-truncating mutations based on data related to the c.1100delC variant, consistent with recommendations from other experts [
         <a href="#rid18">
          18,19,22
         </a>
         ].
        </p>
        <p>
         <em>
          CHEK2
         </em>
         heterozygotes (carriers) of the c.1100delC variant are significantly more likely to be younger at the time of breast cancer diagnosis (mean age 50 years), have a family history of breast cancer, develop estrogen receptor (ER)-positive breast cancer, and develop a second primary breast cancer [
         <a href="#rid14">
          14,23
         </a>
         ]. Risk for breast cancer is also increased perhaps by as much as 10-fold in males who carry the c.1100delC variant, although the absolute risk is low [
         <a href="#rid24">
          24
         </a>
         ].
        </p>
        <p>
         Individuals with pathogenic missense variants may be counseled similarly to those with the c.Ile157Thr variant, or counseling may be individualized based on available data.
        </p>
        <p class="headingAnchor" id="H1072239143">
         <span class="h4">
          Other cancers
         </span>
         <span class="headingEndMark">
          —
         </span>
         The risks for other
         <em>
          CHEK2
         </em>
         -associated cancers are not as well defined. However, the c.1100delC variant appears to be associated with an increased risk for colorectal cancer, particularly in the setting of a family history of colorectal cancer [
         <a href="#rid25">
          25
         </a>
         ]. For example, the cumulative risk of colorectal cancer for c.1100delC carriers to age 49 is estimated to be 0.6 percent, with a cumulative lifetime risk to age 85 of approximately 12 percent [
         <a href="#rid22">
          22
         </a>
         ]. In addition, the cumulative risk of colorectal cancer for the c.Ile157Thr variant is estimated to be 0.5 percent by age 49, with a cumulative lifetime risk to age 85 of approximately 12 percent [
         <a href="#rid22">
          22
         </a>
         ]. These
         <em>
          CHEK2
         </em>
         -associated risks compare with a lifetime risk in the general population of approximately 6 percent. (See
         <a class="medical medical_review" href="/z/d/html/785.html" rel="external">
          "Overview of hereditary breast and ovarian cancer syndromes", section on 'CHEK2'
         </a>
         .)
        </p>
        <p>
         Studies have also found individuals with a pathogenic variant in
         <em>
          CHEK2
         </em>
         have increased risks for prostate and thyroid cancers [
         <a href="#rid5">
          5,26
         </a>
         ], with some evidence suggesting increased risks for kidney, colon, and stomach cancers, as well as sarcoma [
         <a href="#rid5">
          5,19
         </a>
         ], although these risks are not well established. Convincing evidence that
         <em>
          CHEK2
         </em>
         pathogenic variants confer an increased risk of ovarian cancer are lacking [
         <a href="#rid27">
          27,28
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3386046062">
         <span class="h2">
          Management
         </span>
         <span class="headingEndMark">
          —
         </span>
         We generally adhere to National Comprehensive Cancer Network (NCCN) recommendations for surveillance and risk reduction. Counseling may require additional visits or referrals [
         <a href="#rid29">
          29
         </a>
         ]. Acting upon genetic test results is rarely an emergency; the individual can be reassured that management decisions can be deferred until questions are answered.
        </p>
        <p>
         Findings in family members (type of cancers, age of onset) may also inform recommendations about surveillance (eg, starting at an earlier age if a family member has an earlier age of onset) or risk reduction.
        </p>
        <p>
         We consider all individuals with a pathogenic or likely pathogenic variant in
         <em>
          CHEK2
         </em>
         to be at risk for
         <em>
          CHEK2-
         </em>
         asociated cancers, regardless of the initial reason for testing. (See
         <a class="local">
          'Disease associations'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H2586482512">
         <span class="h3">
          Cancer screening
         </span>
         <span class="headingEndMark">
          —
         </span>
         The following screening is appropriate for individuals who are heterozygous for a pathogenic variant in
         <em>
          CHEK2
         </em>
         (
         <em>
          CHEK2
         </em>
         carriers):
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Breast cancer
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         For females, we typically initiate annual mammography with tomography and annual magnetic resonance imaging (MRI) with gadolinium starting at age 40 years. Examinations can be staggered so that one occurs every six months. The age to initiate breast cancer screening is modified based on family history and should begin 5 to 10 years earlier than the youngest breast cancer diagnosis in the family, but no later than age 40 years.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Evidence is insufficient to recommend risk-reducing mastectomy in
         <em>
          CHEK2
         </em>
         carriers, regardless of whether or not they have had cancer. However, female carriers, especially those with a family history of breast cancer or other risks factors (eg, atypia or a breast cancer diagnosis), can consider this option and discuss the potential benefits, risks, and limitations with their providers.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         For female carriers with a concerning family history who do not undergo risk-reducing mastectomy, chemoprevention with endocrine therapy may be an appropriate option (see
         <a class="medical medical_review" href="/z/d/html/756.html" rel="external">
          "Selective estrogen receptor modulators and aromatase inhibitors for breast cancer prevention", section on 'Indications'
         </a>
         ). In particular, females with a pathogenic variant in
         <em>
          CHEK2
         </em>
         are more likely to develop ER-positive breast cancer and thus may be good candidates for chemoprevention with a selective estrogen response modifier (SERM) such as
         <a class="drug drug_general" data-topicid="9972" href="/z/d/drug information/9972.html" rel="external">
          tamoxifen
         </a>
         , or if postmenopausal, with
         <a class="drug drug_general" data-topicid="9593" href="/z/d/drug information/9593.html" rel="external">
          raloxifene
         </a>
         or an aromatase inhibitor. However, data regarding efficacy specifically in
         <em>
          CHEK2
         </em>
         carriers are lacking.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         The absolute risk of male breast cancer is very low. Therefore, we do not pursue screening mammography or risk-reducing mastectomy in male carriers.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Ovarian cancer
         </strong>
         — Pathogenic variants in
         <em>
          CHEK2
         </em>
         do not appear to confer an increased risk for ovarian cancer. For those with a family history of ovarian cancer, we discuss the potential risks and benefits of risk-reducing bilateral salpingo-oophorectomy. (See
         <a class="medical medical_review" href="/z/d/html/785.html" rel="external">
          "Overview of hereditary breast and ovarian cancer syndromes", section on 'CHEK2'
         </a>
         and
         <a class="local">
          'Cancer risks'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Colorectal cancer
         </strong>
         — We recommend colorectal cancer screening with a colonoscopy rather than other colorectal cancer screening modalities [
         <a href="#rid30">
          30
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         For those without a first-degree relative with colorectal cancer, colonoscopy is performed every five years, beginning at age 40.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         For those with a first-degree relative with colorectal cancer, colonoscopy is performed every five years beginning either at age 40, or 10 years prior to the age of the first-degree relative's age at colorectal cancer diagnosis.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Other cancers
         </strong>
         —
         <strong>
         </strong>
         Male
         <em>
          CHEK2 car
         </em>
         riers should review their family history of prostate cancer and discuss prostate cancer screening options (prostate-specific antigen [PSA], digital rectal exam) with their physician to determine an appropriate surveillance regimen. These discussions could be initiated at age 40. There are no other specific recommendations for increased cancer screening in
         <em>
          CHEK2 carr
         </em>
         iers, but as always, individualized screening may be appropriate based on the family history or other risk factors. (See
         <a class="medical medical_review" href="/z/d/html/112282.html" rel="external">
          "Genetic risk factors for prostate cancer", section on 'CHEK2'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H629060218">
         <span class="h3">
          Considerations for the family
         </span>
        </p>
        <p class="headingAnchor" id="H4023100917">
         <span class="h4">
          Reproductive counseling
         </span>
         <span class="headingEndMark">
          —
         </span>
         Reproductive counseling (ideally done prior to conception) is appropriate for individuals with a pathogenic or likely pathogenic variant in
         <em>
          CHEK2
         </em>
         who are considering childbearing or may wish to have children in the future.
        </p>
        <p>
         Some may elect to conceive using donor gametes or in vitro fertilization (IVF) with preimplantation genetic testing (PGT). Testing is also available during a pregnancy or after birth. (See
         <a class="medical medical_review" href="/z/d/html/6783.html" rel="external">
          "Preimplantation genetic testing", section on 'Patients known to be at increased risk of offspring with a specific medically actionable condition'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H816921514">
         <span class="h4">
          Genetic testing of at-risk relatives
         </span>
         <span class="headingEndMark">
          —
         </span>
         Individuals who test positive for a pathogenic or likely pathogenic variant should inform their relatives about the importance of genetic counseling and the option of possible testing.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The risk of having inherited the variant is 50 percent for first-degree relatives (parents, male and female siblings, children). Other at-risk relatives may include aunts, uncles, nieces, nephews, and cousins.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Genetic testing is generally deferred until ≥18 years of age to allow for informed consent because it is very rare for
         <em>
          CHEK2-
         </em>
         associated cancers to occur before adulthood. (See
         <a class="local">
          'Resources'
         </a>
         below and
         <a class="medical medical_review" href="/z/d/html/2901.html" rel="external">
          "Genetic testing", section on 'Ethical, legal, and psychosocial issues'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1334178791">
         <span class="h1">
          IMPLICATIONS OF A NEGATIVE TEST
         </span>
         <span class="headingEndMark">
          —
         </span>
         Negative testing means no pathogenic variants were identified  (
         <a class="graphic graphic_algorithm graphicRef138683" href="/z/d/graphic/138683.html" rel="external">
          algorithm 1
         </a>
         ). However, such results do not necessarily mean that hereditary risk is ruled out or that cancer risks for the tested individual are not elevated.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Once a familial
         <em>
          CHEK2
         </em>
         pathogenic variant is identified and the tested individual does not have that variant, they may be reassured that they are unlikely to be at high risk for
         <em>
          CHEK2
         </em>
         -associated cancers, with the caveats outlined above (see
         <a class="local">
          'How to read the report'
         </a>
         above). However, it is important to assess both sides of the family history, as well as other personal cancer risk factors to provide an individualized risk assessment. As with variants in other genes in which the risk assessment is particularly dependent on family history, relatives who test negative for the familial pathogenic variant may not have cancer risks that are reduced to the level of the general population [
         <a href="#rid18">
          18,31
         </a>
         ]. Thus, unlike at-risk individuals in
         <em>
          BRCA1/2-
         </em>
         positive kindreds who receive a "true negative" result and can usually be reassured that their breast and ovarian cancer risks are about the same as the general population [
         <a href="#rid32">
          32,33
         </a>
         ], such reassurance may not always be possible when there is a
         <em>
          CHEK2
         </em>
         pathogenic variant in the family.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         If a familial variant in
         <em>
          CHEK2
         </em>
         is not known and results of genetic testing are negative, additional risk factors for cancer (genetic or environmental) may still be present. Depending on the extent of genetic testing performed, additional testing (eg, with a multigene panel) may be indicated. Surveillance and risk reduction recommendations are based on personal risk factors and family history. Referral to a clinical geneticist, oncologist, or genetic counselor may be helpful to determine optimal testing in those with a strong or suggestive family history of cancer. (See
         <a class="local">
          'Locating a genetics expert'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H23907703">
         <span class="h1">
          VARIANT OF UNCERTAIN SIGNIFICANCE
         </span>
         <span class="headingEndMark">
          —
         </span>
         Individuals with a variant of uncertain significance (VUS) should be managed based on their personal and family history and not the VUS  (
         <a class="graphic graphic_algorithm graphicRef138683" href="/z/d/graphic/138683.html" rel="external">
          algorithm 1
         </a>
         ).
        </p>
        <p>
         New information may become available, and the testing laboratory or other resources should be consulted periodically for updates in the classification (eg, annually). (See
         <a class="local">
          'Classification of variants'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H2112537530">
         <span class="h1">
          RESOURCES
         </span>
        </p>
        <p class="headingAnchor" id="H1678774184">
         <span class="h2">
          UpToDate topics
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <em>
          CHEK2
         </em>
         associated risks:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Cancer risks – (See
         <a class="medical medical_review" href="/z/d/html/785.html" rel="external">
          "Overview of hereditary breast and ovarian cancer syndromes", section on 'CHEK2'
         </a>
         .)
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Genetic testing – (See
         <a class="medical medical_review" href="/z/d/html/753.html" rel="external">
          "Genetic testing and management of individuals at risk of hereditary breast and ovarian cancer syndromes"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Genetics:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Variant classification – (See
         <a class="medical medical_review" href="/z/d/html/96539.html" rel="external">
          "Secondary findings from genetic testing", section on 'Definitions and classification of variants'
         </a>
         .)
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Terminology – (See
         <a class="medical medical_review" href="/z/d/html/2898.html" rel="external">
          "Genetics: Glossary of terms"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2512094878">
         <span class="h2">
          Locating a genetics expert
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Clinical geneticists – American College of Medical Genetics and Genomics (
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fclinics.acmg.net%2F&amp;token=nbsXe3i4qfUea5RCPRHtOdEP95SDL7NSm8b1jbZpdwjlW9H1hfmmq%2FTbAbE64qhV&amp;TOPIC_ID=135009" target="_blank">
          ACMG
         </a>
         )
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Genetic counselors – National Society of Genetic Counselors (
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Ffindageneticcounselor.nsgc.org%2F&amp;token=AU2cQkyAZolWVu502Wzur%2F2gjdsB%2FYlqRYYyoKtNflwwaDFffULns7AVKZBF0Vtm&amp;TOPIC_ID=135009" target="_blank">
          NSGC
         </a>
         )
        </p>
        <p>
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li class="breakAll">
          Supporting references are provided in the associated UpToDate topics, with selected citation(s) below.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Richards S, Aziz N, Bale S, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med 2015; 17:405.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mighton C, Charames GS, Wang M, et al. Variant classification changes over time in BRCA1 and BRCA2. Genet Med 2019; 21:2248.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kuschel B, Auranen A, Gregory CS, et al. Common polymorphisms in checkpoint kinase 2 are not associated with breast cancer risk. Cancer Epidemiol Biomarkers Prev 2003; 12:809.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Näslund-Koch C, Nordestgaard BG, Bojesen SE. Increased Risk for Other Cancers in Addition to Breast Cancer for CHEK2*1100delC Heterozygotes Estimated From the Copenhagen General Population Study. J Clin Oncol 2016; 34:1208.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Meijers-Heijboer H, Wijnen J, Vasen H, et al. The CHEK2 1100delC mutation identifies families with a hereditary breast and colorectal cancer phenotype. Am J Hum Genet 2003; 72:1308.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sodha N, Bullock S, Taylor R, et al. CHEK2 variants in susceptibility to breast cancer and evidence of retention of the wild type allele in tumours. Br J Cancer 2002; 87:1445.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vahteristo P, Bartkova J, Eerola H, et al. A CHEK2 genetic variant contributing to a substantial fraction of familial breast cancer. Am J Hum Genet 2002; 71:432.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ingvarsson S, Sigbjornsdottir BI, Huiping C, et al. Mutation analysis of the CHK2 gene in breast carcinoma and other cancers. Breast Cancer Res 2002; 4:R4.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vahteristo P, Tamminen A, Karvinen P, et al. p53, CHK2, and CHK1 genes in Finnish families with Li-Fraumeni syndrome: further evidence of CHK2 in inherited cancer predisposition. Cancer Res 2001; 61:5718.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Evans DG, Birch JM, Narod SA. Is CHEK2 a cause of the Li-Fraumeni syndrome? J Med Genet 2008; 45:63.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schmidt MK, Tollenaar RA, de Kemp SR, et al. Breast cancer survival and tumor characteristics in premenopausal women carrying the CHEK2*1100delC germline mutation. J Clin Oncol 2007; 25:64.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Guénard F, Pedneault CS, Ouellette G, et al. Evaluation of the contribution of the three breast cancer susceptibility genes CHEK2, STK11, and PALB2 in non-BRCA1/2 French Canadian families with high risk of breast cancer. Genet Test Mol Biomarkers 2010; 14:515.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Weischer M, Nordestgaard BG, Pharoah P, et al. CHEK2*1100delC heterozygosity in women with breast cancer associated with early death, breast cancer-specific death, and increased risk of a second breast cancer. J Clin Oncol 2012; 30:4308.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schmidt MK, Hogervorst F, van Hien R, et al. Age- and Tumor Subtype-Specific Breast Cancer Risk Estimates for CHEK2*1100delC Carriers. J Clin Oncol 2016; 34:2750.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Narod SA. Testing for CHEK2 in the cancer genetics clinic: ready for prime time? Clin Genet 2010; 78:1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cybulski C, Wokołorczyk D, Jakubowska A, et al. Risk of breast cancer in women with a CHEK2 mutation with and without a family history of breast cancer. J Clin Oncol 2011; 29:3747.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tung N, Domchek SM, Stadler Z, et al. Counselling framework for moderate-penetrance cancer-susceptibility mutations. Nat Rev Clin Oncol 2016; 13:581.
          </a>
         </li>
         <li class="breakAll">
          National Comprehensive Cancer Network (NCCN) guidelines. Genetic/familial high-risk assessment: Breast, ovarian, and pancreatic, version 2.2022. Available at: https://www.nccn.org/guidelines/guidelines-detail?category=2&amp;id=1503 (Accessed on March 29, 2022).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Weischer M, Bojesen SE, Ellervik C, et al. CHEK2*1100delC genotyping for clinical assessment of breast cancer risk: meta-analyses of 26,000 patient cases and 27,000 controls. J Clin Oncol 2008; 26:542.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Han FF, Guo CL, Liu LH. The effect of CHEK2 variant I157T on cancer susceptibility: evidence from a meta-analysis. DNA Cell Biol 2013; 32:329.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Katona BW, Yurgelun MB, Garber JE, et al. A counseling framework for moderate-penetrance colorectal cancer susceptibility genes. Genet Med 2018; 20:1324.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kriege M, Hollestelle A, Jager A, et al. Survival and contralateral breast cancer in CHEK2 1100delC breast cancer patients: impact of adjuvant chemotherapy. Br J Cancer 2014; 111:1004.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Meijers-Heijboer H, van den Ouweland A, Klijn J, et al. Low-penetrance susceptibility to breast cancer due to CHEK2(*)1100delC in noncarriers of BRCA1 or BRCA2 mutations. Nat Genet 2002; 31:55.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Xiang HP, Geng XP, Ge WW, Li H. Meta-analysis of CHEK2 1100delC variant and colorectal cancer susceptibility. Eur J Cancer 2011; 47:2546.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cybulski C, Górski B, Huzarski T, et al. CHEK2 is a multiorgan cancer susceptibility gene. Am J Hum Genet 2004; 75:1131.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Walsh T, Casadei S, Lee MK, et al. Mutations in 12 genes for inherited ovarian, fallopian tube, and peritoneal carcinoma identified by massively parallel sequencing. Proc Natl Acad Sci U S A 2011; 108:18032.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           LaDuca H, Stuenkel AJ, Dolinsky JS, et al. Utilization of multigene panels in hereditary cancer predisposition testing: analysis of more than 2,000 patients. Genet Med 2014; 16:830.
          </a>
         </li>
         <li class="breakAll">
          Genetic/familial high-risk assessment: colorectal 2.2022. NCCN clinical practice guidelines in oncology. Available at: https://www.nccn.org/login?ReturnURL=https://www.nccn.org/professionals/physician_gls/pdf/genetics_colon.pdf (Accessed on March 21, 2023).
         </li>
         <li class="breakAll">
          National Comprehensive Cancer Network (NCCN) guidelines. Genetic/Familial high-risk assessment: Colorectal, version 1.2021. Available at: https://www.nccn.org/guidelines/guidelines-detail?category=2&amp;id=1436 (Accessed on April 11, 2022).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lee AJ, Cunningham AP, Tischkowitz M, et al. Incorporating truncating variants in PALB2, CHEK2, and ATM into the BOADICEA breast cancer risk model. Genet Med 2016; 18:1190.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Korde LA, Mueller CM, Loud JT, et al. No evidence of excess breast cancer risk among mutation-negative women from BRCA mutation-positive families. Breast Cancer Res Treat 2011; 125:169.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Girardi F, Barnes DR, Barrowdale D, et al. Risks of breast or ovarian cancer in BRCA1 or BRCA2 predictive test negatives: findings from the EMBRACE study. Genet Med 2018; 20:1575.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 135009 Version 3.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="javascript:alert('بدون لینک');" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Supporting references are provided in the associated UpToDate topics, with selected citation(s) below.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25741868" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30971832" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Variant classification changes over time in BRCA1 and BRCA2.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12917215" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Common polymorphisms in checkpoint kinase 2 are not associated with breast cancer risk.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26884562" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Increased Risk for Other Cancers in Addition to Breast Cancer for CHEK2*1100delC Heterozygotes Estimated From the Copenhagen General Population Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12690581" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : The CHEK2 1100delC mutation identifies families with a hereditary breast and colorectal cancer phenotype.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12454775" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : CHEK2 variants in susceptibility to breast cancer and evidence of retention of the wild type allele in tumours.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12094328" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : A CHEK2 genetic variant contributing to a substantial fraction of familial breast cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12052256" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Mutation analysis of the CHK2 gene in breast carcinoma and other cancers.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11479205" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : p53, CHK2, and CHK1 genes in Finnish families with Li-Fraumeni syndrome: further evidence of CHK2 in inherited cancer predisposition.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18178638" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Is CHEK2 a cause of the Li-Fraumeni syndrome?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17132695" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Breast cancer survival and tumor characteristics in premenopausal women carrying the CHEK2*1100delC germline mutation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20722467" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Evaluation of the contribution of the three breast cancer susceptibility genes CHEK2, STK11, and PALB2 in non-BRCA1/2 French Canadian families with high risk of breast cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23109706" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : CHEK2*1100delC heterozygosity in women with breast cancer associated with early death, breast cancer-specific death, and increased risk of a second breast cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27269948" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Age- and Tumor Subtype-Specific Breast Cancer Risk Estimates for CHEK2*1100delC Carriers.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20597917" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Testing for CHEK2 in the cancer genetics clinic: ready for prime time?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21876083" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Risk of breast cancer in women with a CHEK2 mutation with and without a family history of breast cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27296296" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Counselling framework for moderate-penetrance cancer-susceptibility mutations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27296296" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Counselling framework for moderate-penetrance cancer-susceptibility mutations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18172190" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : CHEK2*1100delC genotyping for clinical assessment of breast cancer risk: meta-analyses of 26,000 patient cases and 27,000 controls.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23713947" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : The effect of CHEK2 variant I157T on cancer susceptibility: evidence from a meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29493579" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : A counseling framework for moderate-penetrance colorectal cancer susceptibility genes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24918820" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Survival and contralateral breast cancer in CHEK2 1100delC breast cancer patients: impact of adjuvant chemotherapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11967536" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Low-penetrance susceptibility to breast cancer due to CHEK2(*)1100delC in noncarriers of BRCA1 or BRCA2 mutations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21807500" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Meta-analysis of CHEK2 1100delC variant and colorectal cancer susceptibility.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15492928" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : CHEK2 is a multiorgan cancer susceptibility gene.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22006311" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Mutations in 12 genes for inherited ovarian, fallopian tube, and peritoneal carcinoma identified by massively parallel sequencing.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24763289" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Utilization of multigene panels in hereditary cancer predisposition testing: analysis of more than 2,000 patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24763289" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Utilization of multigene panels in hereditary cancer predisposition testing: analysis of more than 2,000 patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24763289" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Utilization of multigene panels in hereditary cancer predisposition testing: analysis of more than 2,000 patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27464310" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Incorporating truncating variants in PALB2, CHEK2, and ATM into the BOADICEA breast cancer risk model.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20458532" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : No evidence of excess breast cancer risk among mutation-negative women from BRCA mutation-positive families.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29565421" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Risks of breast or ovarian cancer in BRCA1 or BRCA2 predictive test negatives: findings from the EMBRACE study.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
